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Yeast has been established as an efﬁcient model system to study biological principles
underpinning human health. In this review we focus on yeast models covering two
aspects of cancer formation and progression (i) the activity of pyruvate kinase (PK), which
recapitulates metabolic features of cancer cells, including the Warburg effect, and (ii)
chromosome bridge-induced translocation (BIT) mimiking genome instability in cancer.
Saccharomyces cerevisiae is an excellent model to study cancer cell metabolism, as expo-
nentially growing yeast cells exhibit many metabolic similarities with rapidly proliferating
cancer cells. The metabolic reconﬁguration includes an increase in glucose uptake and
fermentation, at the expense of respiration and oxidative phosphorylation (the Warburg
effect), and involves a broad reconﬁguration of nucleotide and amino acid metabolism.
Both in yeast and humans, the regulation of this process seems to have a central player,
PK, which is up-regulated in cancer, and to occur mostly on a post-transcriptional and post-
translational basis. Furthermore, BIT allows to generate selectable translocation-derived
recombinants (“translocants”), between any two desired chromosomal locations, in
wild-type yeast strains transformedwith a linear DNA cassette carrying a selectablemarker
ﬂanked by two DNA sequences homologous to different chromosomes. Using the BIT
system, targeted non-reciprocal translocations in mitosis are easily inducible. An extensive
collection of different yeast translocants exhibiting genome instability and aberrant
phenotypes similar to cancer cells has been produced and subjected to analysis. In this
review, we hence provide an overview upon two yeast cancer models, and extrapolate
general principles for mimicking human disease mechanisms in yeast.
Keywords: aneuploidy, cancer, chromosome translocation, double-strand break, genome stability, pentose-
phosphate pathway,Warburg effect, yeast model system
INTRODUCTION
Yeast (Saccharomyces cerevisiae) and human split around a bil-
lion years ago, therefore a plethora of cellular mechanisms have
evolved in parallel. However, at the same time many fundamental
processes remain strongly conserved, and thus yeast represents an
efﬁcient utility that can help to understand the molecular mecha-
nisms underlying human disease physiology. Although many yeast
models for studying cancer have been established (reviewed in
Pereira et al., 2012), we here focus on two physiological processes
that appear to be deeply similar between yeast and humans: (i) the
reprograming of central metabolism during rapid cell growth
[glycolysis, the pentose-phosphate pathway (PPP), amino acid
metabolism, and respiration], bearing similarities to the Warburg
effect in cancer cells (Bayley and Devilee, 2011; Cairns et al., 2011;
Grüning and Ralser, 2011), and (ii) the bridge-induced transloca-
tion (BIT) system and its genetic and physiological consequences
(Tosato et al., 2005, 2009; Nikitin et al., 2008; Rossi et al., 2010),
which resemble and perhaps could simulate genomic instability of
leukemia cells.
The majority of cancer research institutions around the world
use yeast genetics as part of their research strategy and at least
two of them are (or were) led by Nobel laureates who achieved
their major honors for research accomplished in yeasts (Leland
H. Hartwell and Paul Nurse, who together with Tim Hunt were
awarded the 2001 Nobel prize in Physiology or Medicine for their
work on the eukaryotic cell cycle). S. cerevisiae remains promi-
nent in research of basics of eukaryotic molecular cell biology.
Undisputedly, this yeast is a very advantageous system for this
purpose: S. cerevisiae cells are rapidly growing and easy to handle,
have a short cell cycle and use a large number (but not all) of the
molecular genetic mechanisms known from multicellular organ-
isms. Most importantly, yeast is the most highly developed system
amenable to change its genome by genetic engineering, reintro-
ducing precisely engineered genetic changes into the genome and
to study the effects of those manipulations in vivo, in short, to do
“reverse genetics.”This is in particular true for cell cycle regulation,
mutagenesis, andDNA repair, and the suicide process of apoptosis,
all of which have been found to be important for understanding
the biology of cancer cells. To give an example and a quote, the
motivation of Lee Hartwell to do cell cycle research in yeast was
that he wanted to contribute to the understanding of cancer. He
started his Nobel lecture with these words: "My research career has
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been motivated by a desire to understand cancer. Each time I have
identiﬁed an intriguing aspect of the cancer problem, I found that
it could be approached more effectively in the simple eukaryotic
cell, S. cerevisiae, than in the human cell” (Hartwell, 2004). The key
point is to mimic, if possible, the pathological changes observed
in cancer cells in yeast cells and then to manipulate these model
phenocopies in order to try to reduce the effects of those changes.
Examples would be the loss of cell cycle checkpoints in cancer cells
and the loss of pathways to enter the apoptotic program.
COMPARATIVE GENOMICS
The prediction that nearly half (∼3,000) of all yeast genes would
have structural or functional homologs in the human genome,
promptedmany comparative genetic studies between the yeast and
mammalian cell systems. Indeed, several yeast orthologs exist of
human genes considered tumor suppressors important for tumor
initiation and/or progression. For other genes, like the human p53
tumor suppressor and cell cycle checkpoint gene, even if there is
no direct yeast ortholog itself, an analogous signal transduction
pathway in which it participates does exist. The human protein
can be expressed in yeast, where the mutations occurring in this
gene and their phenotypic consequences can be studied much
easier. In this way, themutational spectrumof p53was determined
and found to be identical to the one found in human cancers
(Brachmann et al., 1996; Inga et al., 1998; Schlichtholz et al., 2004).
Since the genetic system of yeast allows for the selection of speciﬁc
types of mutants, for instance dominant negative mutations, the
spectrumof dominant negativemutations of p53 obtained in yeast
was then found identical to the mutational spectrum in cancers
(Brachmann et al., 1996).
New anti-cancer drugs that ideally should interfere with the
special pathological processes of cancer cells without harming
normal cells are being tested in yeast cells mimicking “cancer-like”
genetic (mutants defective in checkpoints) or environmental (cells
under severe oxidative stress) conditions. The efﬁcacy of these
drugs often depends on a “synthetic lethal” effect. For instance,
as a driving mutation inactivates a certain repair pathway, the
drug inhibits the only other remaining parallel repair pathway in
the cancer cell (Bjornsti, 2002; Hartwell, 2004). As outlined by
Hartwell, these strategies have already proved very valuable for
broadening the understanding of cancer development and treat-
ments given to patients. As example, our understanding of the
molecular mechanism of action of cancer drugs which inhibit
topoisomerase II or the proofreading activity of DNA polymerases
has improved greatly using a panel of 70 yeast strains that are
defective in exactly those highly conserved cell cycle, checkpoint,
or DNA repair functions which are also found in clinical cancer
specimens (Hartwell, 2004). Therefore, therapies can be developed
and improved, if the relevant biochemical defect of the cancer in
question is determined. A more exotic approach is to use yeast cells
or substances derived from yeast cells as a cancer cure (Ghoneum
and Gollapudi, 2004; Liu et al., 2009) that is, however, not the topic
of this review.
GENOME STABILITY AND MAINTENANCE
An important contribution of yeast research to our understanding
of cancer arose from genome-wide screenings for mutations that
decrease genomic stability (Yuen et al., 2007; Stirling et al., 2011).
This concerns missegregation of chromosomes resulting in aneu-
ploidy, chromosome mutations like translocations, inversions and
deletions, and also point mutations. Both the mitochondrial and
the nuclear genomes were considered for these lines of research.
Also included in these attempts are investigations of aging cells
that were found to show an increased level of genetic instability. In
the last few years, these attempts were supported by an increasing
number of whole genome sequences of human tumor cells. These
sequences identiﬁed hundreds of mutations in those tumors and
have resulted in the identiﬁcation of new cancer-relevant genes,
including CIN (chromosomal instability) alleles (Bignell et al.,
2010). We believe that the genetic changes that give rise to the
genetic instability of tumor cells may provide the key to tumor cell
sensitivity (Hartwell et al., 1997).
The occurrence of genomic instability is an almost universal
marker of cancer cells, but it is less clear if mutations lead-
ing to genomic instability are the most important early “driver”
mutations which clonally initiate cancers (Michor et al., 2005).
This view is now enlarged by the ﬁndings of Marie Hardwick in
yeast (personal communication) showing that in a majority of all
the deletion mutants which she looked at in their yeast collec-
tion, secondary mutations were quite unexpectedly (but rapidly)
selected and occurred in the strains as they were distributed out.
These secondary mutations were in multiple genes and also repre-
sented multiple alleles within the same gene (example: WHI2).
This genomic instability could be due to the selective forces
that apparently work in a genome where a functional gene has
been lost.
It is also not clear if a single chromosomal translocation event
can be sufﬁcient to trigger the complex chain of events that we call
tumor progression. This is the case in certain leukemias, the most
well known of which are chronic myelogenic leukemia (CML)
and acute myeloid leukemia caused by the translocation event
of the Philadelphia chromosome (Sherbenou and Druker, 2007).
At the present, even if the earliest direct demonstrations of the
role of chromosomal translocations as causative agents of tumors
were found in liquid tumors, there are nevertheless numerous
examples, even in epithelial tumors, of the pathogenic effect of
these translocations in solid tumors as well.
Wewould like to ask the question as to“whatwould conceivably
be the phenotype of yeast cells that can serve as a model for human
cancer cells?” To many people’s opinion, unrestricted growth is
the most problematic phenotype of cancer cells. Normal wild-
type yeast cells recapitulate this phenotype: on rich media, cells
multiply and the biomass grows until nutrients, or one essential
nutrient, are used up. However, wild-type cells are able to respond
to the level of all essential nutrients, and to many other condi-
tions (for instance, the presence of an alpha mating partner in an
a-cell) in an ordered and life-promoting fashion. These responses
work via signal transduction pathways or rather a network of such
signal transduction pathways that regulates the cell cycle. These
mechanisms can stop the cell cycle at junctions that were termed
“checkpoints” by Hartwell and his coworkers (Hartwell and Wein-
ert, 1989; Weinert, 1997). The ﬁnal phenotypic outcome of these
wild-type checkpoint mechanisms is cell cycle arrest (for instance
in response to DNA damage), repair, and if repair does not take
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place, either apoptotic cell death or trans lesion DNA synthe-
sis resulting in a permanent damage to the genome, and hence
genomic instability. These pathological forms of growth and cell
division were not observed frequently in yeast mutants, but they
are hallmarks of human cancer cells.
Early yeast models for cancer signaling, the RAS gene
In one of the ﬁrst valid examples of “cancer phenotypes” in yeast,
the oncogenic point mutation Ha-ras-val12 was compared with a
homologous mutation in a closely related yeast gene, RAS2-val19.
It is well known that this single point mutation can transform
mouse 3T3 cells from an immortalized but harmless cell line into
a highly cancerogenic line leading to numerous cancerogenic foci
in cell culture and to cancers if transplanted into immune deﬁcient
mice (Weinberg, 1983). The same mutation in yeast (RAS2-val19)
renders yeast cells into being insensitive to the starvation signal(s)
and prevents the synthesis of reserve carbohydrates. Eventually,
this causes cell death during starvation (in particular nitrogen
starvation), a very short mother cell-speciﬁc life span even in
the presence of nutrients, creates oxidative stress and increases
apoptotic death (Tatchell et al., 1985; Toda et al., 1985). Biochem-
ically, the two homologous mutant genes in yeast and human
cells render the small G protein RAS insensitive to regulatory pro-
teins (GAPs and GEFs), keep it in a permanently activated state
and therefore permanently activate the ensuing signal transduc-
tion cascade. Interestingly, although the downstream kinases are
different in yeast and human cells, the observed changes result-
ing from the activating ras mutation are similar in both systems.
If the human Ha-ras-val12 mutation is tested in an otherwise
wild-type cell, it leads to hypermitogenic arrest and apoptosis,
just as in the yeast cell (Serrano et al., 1997). Only if other typ-
ical mutations of cancer cells are present, the murine cells are
transformed to acquire cancerous growth. This example shows
what can be expected from yeast cells that model cancer cells and
which cancer phenotypes can be studied in yeast. In our view,
two of the most telling and pathogenetically relevant phenotypes
of cancer cells are their genomic instability and the remodeling
of metabolism to a hypoxic-like state although oxygen is present
in those cells at levels comparable to wild-type non-cancerous
cells. Little or nothing is presently known about the interrela-
tionship of these two phenotypes. The latter one is also known
as the Warburg effect and has recently experienced a renaissance
of intensive investigations among cancer researchers. Genomic
instability occurs in the majority if not in all cancer cells, but
the role and history of subsequent steps of genomic instability
during tumor progression is hard to study because early stages
of cancers are usually not available in clinical samples. It is
unclear how and why a ﬁnal step in tumor progression results
in a highly aneuploid but ﬁnally stable endpoint and what the
biochemical commonalities are between those vastly different can-
cer cells, which are all highly aneuploid. For those reasons, a
number of groups have tried to deﬁne mutations in genes which
are normally responsible for genomic stability and lead to strong
mutator phenotypes resulting in chromosome loss or gross chro-
mosomal rearrangements (GCR) in certain mutants. It is now
possible but very difﬁcult to perform such a study in human cells
(Paulsen et al., 2009). However, the yeast genetic system has been
exploited for this purpose and has led to a comprehensive set of
both non-essential (Yuen et al., 2007) and essential genes (Stirling
et al., 2011) which, when mutated, contribute to genomic insta-
bility. The yeast system has the additional advantage to deﬁne
whole sets of genes and physiological pathways through interac-
tion networks, which also contributes to genome maintenance.
The endpoints used for the genome-wide screening of both the
yeast deletion collection and several collections of conditional
mutations in essential genes were (i) loss of a centromeric chro-
mosome fragment and screening for ade2-mutant colony color;
(ii) screening for bi-maters; (iii) screening for a-like fakers; and
(iv) screening for GCRs by simultaneously scoring forward muta-
tion to canR and loss of URA3 on 5-ﬂuoroorotic acid (5-FOA)
(Stirling et al., 2011). A total of 692 genes was identiﬁed in func-
tional classes (GO terms) that are highly plausible based on prior
knowledge of genome maintenance (mitosis, replication, repair,
DNA modiﬁcation, telomere maintenance, transcription, RNA
processing, nuclear transport, and proteasome) or deﬁne periph-
eral functions, like iron-sulfur cluster biosynthesis (Veatch et al.,
2009). Most importantly, some of the most central and most
highly conserved of those genes have human orthologs, mutant
alleles of which were found in tumor specimens – among them,
SGS1 (human genes BLM and WRN, repair helicase), MRE11
(MRE11A, the gene of a syndrome related to ataxia telangiecta-
sia), DUN1 (CHK2, one of the genes of familial Li–Fraumeni
syndrome, coding for a cell cycle checkpoint protein), and BUB1
(BUB1, frequently mutated in colorectal cancer). These ﬁnd-
ings are proof of principle for the usefulness of this approach
to study genome instability in yeast as an avenue to understand
genome instability in cancers. The consensus among the authors
in this ﬁeld is that genome instability can probably be a primary
cause creating the other mutations found in cancers and consti-
tuting the tumor progression sequence. A similar conclusion was
reached by analyzing clinical data with a mathematical model in
light of the “two hit” hypothesis (Michor et al., 2005). The acti-
vation of error prone DNA synthesis, which then indirectly leads
to more mutations including point mutations, is another impor-
tant consequence of genome instability (Daee et al., 2010). This
can happen both by activating error prone DNA polymerases
that exist in all cells for different purposes, and also by pro-
ducing mutant forms of the replicative DNA polymerases, which
for instance have lost their proofreading exonuclease functions
(Daee et al., 2010).
We believe that BIT in diploid yeast cells (Tosato et al., 2005),
which leads to unstable genomes, can be a valid model system
to study the role and the physiological consequences of genomic
instability. This system consists of the artiﬁcial induction of chro-
mosome translocation based upon the DNA transformation of
wild-type yeast cells with a linear, double-stranded DNA molecule
(cassette) obtained by PCR. The DNA cassette has the two ends
with a sequence homologous to two different chromosomal sites
of the genome and ﬂank a positively selectable marker such as
KANR or HYGR. The integration of the two free DNA cassette
ends at their homologous site by homologous recombination,
forms a DNA bridge between two different chromosomes, that
is, a chromosome translocation between them. This event can
be selected screening the cells for the stable appearance of the
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phenotype conferred by the selectable marker carried by the
cassette.
The connection between unstable genomes and metabolic
remodeling can be studied in those cells that have undergone
BIT translocation. Indeed, in these cells, a complex genomic rear-
rangement is triggered after the primary BIT event, leading to
a general status of gene de-regulation that slowly settles down,
selectively remodeling the metabolism according to the environ-
mental conditions of growth, in what is called the adaptation
phase.
STUDYING YEAST PHYSIOLOGY TO EXPLAIN THE WARBURG
EFFECT OF CANCER CELLS
The leading biochemist Otto Warburg described as early as in
the 1920s that tumor tissue ferments at the expense of respiratory
activity (reviewed inWarburg, 1956). He speculated that defects in
mitochondria are thus a cause of cancer. From today’s perspective,
it is known that most cancer cells, with the important exception of
oncocytoma (Mayr et al., 2008), possess a functional respiratory
chain. However, most of them show increased uptake of glucose
(this property is explored in imaging to stain cancer tissue using
the glucose analogous probe 2 ﬂuoro-deoxy-glucose (2FDG; Kur-
toglu et al., 2007)), although many cancers have reduced activity
of oxidative phosphorylation (Ferreira, 2010; Cairns et al., 2011).
From the historical view of metabolism as a producer of energy
and intermediates, this behavior is counterintuitive as mitochon-
drial respiration is more efﬁcient in energy production compared
to anaerobic glycolysis, and the rapid growth of tumors has a
high demand for energy (Cairns et al., 2011; Gruning et al., 2011).
Research of the recent years, involving yeast as central model now
indicates, that metabolic integrity and homeostasis of the system
could explain the necessity of wasting energy, and reconﬁguring
metabolism when growing rapidly.
Yeast recapitulates features of the Warburg effect. At maximum
growth speed, S. cerevisiae strongly prefers fermentation to res-
piration. Hence under conditions where sufﬁcient nutrients are
available, energy (in form of ATP) appears not to be a limit-
ing factor for rapid proliferation. After entering the stationary
phase, yeast growth is slowed and the demand for energy declines.
Interestingly, it is exactly this point where respiration becomes an
important source of energy (van Dijken et al., 1993). This impor-
tant physiological parallelism between most cancer cells and yeast
has prompted a vigorous research in this area.
The yeast S. cerevisiae is a very useful tool in studying the War-
burg effect, as respiratory metabolism can be induced or repressed
easily via switching the carbon source (De Deken, 1966; Crab-
tree effect, described by H. G. Crabtree in the 1920s; Crabtree,
1928). Although they have roughly the same energy content and
are both fermented, glucose represses respiration, but galactose
does not. Ruckenstuhl et al. (2009) used this yeast property to
investigate the effects of respiratory bursts on apoptosis, and the
impact of free radicals on this process. Inhibition of respiration, or
free radical scavenging conferred a survival advantage during seed-
ing and early development of yeast colonies (Ruckenstuhl et al.,
2009). Similarly, cancer cells are reactive oxygen species (ROS)
sensitive, and might proﬁt from anti-oxidant therapies (Perera
and Bardeesy, 2011).
Recent advances in understanding the Warburg effect in can-
cer and yeast came from investigation of the enzyme pyruvate
kinase (PK), which was recognized as a cellular coordinator of
respiration and of the anti-oxidant system. It has been reported
that exchanging the human PK isoform pyruvate kinase muscle
isozyme 2 (PKM2) with its constitutive isozyme PKM1 dra-
matically slows growth of xenograft tumors, and reactivates
respiratory metabolism (Christofk et al., 2008). In this context,
it was assumed that PKM2 is speciﬁc to proliferating tissue, found
only in the embryo or in cancer cells. The lack of other cancer-
speciﬁc metabolic enzymes thus placed PKM2 center stage for
research on cancer cell metabolism (Bayley and Devilee, 2011;
Cairns et al., 2011; Hamanaka and Chandel, 2011). However, a
PKM2 cancer speciﬁcity could not be conﬁrmed in follow up
studies, indeed most adult tissues express PKM2 as their predom-
inant PKM form independent of whether they are cancerous or
healthy (an exception is, however muscle, which expresses PKM1;
Bluemlein et al., 2011). The interpretation of PKM2 being cancer-
speciﬁc thus potentially resulted from using mouse muscle tissue
as non-cancer control in Western blot experiments (Christofk
et al., 2008). Despite this setback, however, PK emerged as a
central regulator of glycolysis, with immense importance for can-
cer (Bayley and Devilee, 2011; Chaneton and Gottlieb, 2012).
Yeast models helped in understanding the global function of this
enzyme.
These results might further help to solve a seemingly para-
dox about PK activity in cancer cells: as discussed by Diaz-Ruiz
et al. (2011), the inhibition of PKM2 seems contradictory in
respect to the high glycolytic ﬂux and increased lactate excre-
tion measured in cancer cells, since an inactive PK would severely
impair cell energy production in the cells that depends mainly
on glycolysis for ATP synthesis. Indeed however, studying PKM2
expression using absolute quantitative mass spectrometry reveals
that PKM2 levels are thoroughly higher in cancer cells than they
are in matched control tissues (as determined in Bluemlein et al.,
2011; please see Figure 1 for an illustration). Thus, although
PKM2 is not to 100% active in cancer, its overall activity might
still be higher as it is in the corresponding control tissue. Indeed,
recent investigations show that PKM2 knock-down increases ﬂux
of the TCA cycle and amino acid metabolism also in cancer cells,
indicating that PKM2 is of considerable residual ﬂux in tumors
(Chaneton et al., 2012).
Similar to PKM proteins in mammalian cells, yeast possesses
twoparalogous PKgenes,PYK1 andPYK2 that encode for enzymes
with related properties. PYK1 encodes for the predominant PK iso-
form when cells grow on glucose media, whereas Pyk2p has lower
speciﬁc activity and is induced under respiring conditions (Boles
et al., 1997). Creating yeast strains with different PK activities (by
ectopic expression of either Pyk1p or Pyk2p at both high and low
level in aΔpyk1Δpyk2 strain) we found that a reduced activity of
this enzyme is sufﬁcient to increase oxygen uptake and respira-
tory activity. Unexpectedly however, strains with lower PK activity
exhibited an increased resistance to several oxidants. Moreover,
although respiring at higher rates, these cells did not show an
increase in the concentration of superoxide and hydrogen per-
oxide, nor did they display features of oxidative stress (Gruning
et al., 2011). This indicated that low PK activity does not only lead
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FIGURE 1 | PKM2 is up-regulated in human cancer. Illustration of the absolute concentrations of PKM2 in several cancer tissues and matched controls,
as determined by liquid chromatography-multiple reaction monitoring (LC-MRM) as described in (Bluemlein et al., 2011). PKM2 levels are clearly increased in
cancer biopsies compared to the controls.
FIGURE 2 | Pyruvate kinase (PK) activity as regulator of anti-oxidant
metabolism. Low activity of PK, found in cancer and in respiring yeast,
leads to increased ﬂux of the pentose phosphate pathway. Increased PPP
activity is required for maintaining the redox balance under conditions with
high ROS load: reduced NADPH is required as redox-power for anti-oxidant
enzymes, and PPP activity stimulates the anti-oxidative gene expression
program.
to increased respiration, it also causes an increase in the anti-
oxidant capacity. This physiological reconﬁguration eventually
compensated for the increased ROS generation during oxidative
metabolism (Figure 2).
Pyruvate kinase converts phosphoenolpyruvate (PEP) to pyru-
vate, a reactionwhich yields onemolecule of ATP (Fraenkel, 1986).
The substrate PEP is a highly polar sugar phosphate, and accu-
mulates in yeast and E. coli when PK activity is low (Emmerling
et al., 2002; Gruning et al., 2011). It has been reported that PEP
can interfere with more than one reaction of glycolysis, including
phosphoglycerate mutase, glucokinase, phosphoglucoisomerase,
phosphofructokinase, aldolase, and triosephosphate isomerase
(TPI; Ogawa et al., 2007; Fenton and Reinhart, 2009; Vander
Heiden et al., 2010). Interestingly, inhibition of the latter was suf-
ﬁcient to increase resistance to oxidants in yeast and C. elegans.
The increase in stress resistance can be attributed to increased
metabolite levels in a metabolic pathway parallel to glycolysis, the
PPP (Ralser et al., 2006, 2007). The PPP shares several metabo-
lites with glycolysis, and plays a pivotal role in the oxidative stress
response. First, this pathway can quickly and dynamically increase
in activity to sufﬁce the increased need for the redox co-factor
NADPH upon an oxidative burst (Ralser et al., 2009). Second, it
is involved in the induction of the anti-oxidant gene expression
program (Kruger et al., 2011). It appears that TPI feedback inac-
tivation by PEP is required for the increase in stress resistance of
the PK mutants, as cells expressing a mutant human TPI allele
(TPIIle170Val) that is largely robust to PEP inhibition do not show
the PK dependent increased resistance to oxidants. Vice versa, in
cells with low PK activity, deletion of the ﬁrst enzyme of the
PPP, glucose-6 phosphate dehydrogenase (ZWF1) causes increased
ROS levels, protein oxidation, and mitochondrial damage (Grun-
ing et al., 2011). In sum, a reduction of PK activity increases
the ﬂux of the PPP protecting against oxidants, and the feed-
back inhibition of TPI by the PK substrate PEP is crucial for this
adaptation.
Although respiring at moderate rates, also cancer cells suffer
from high ROS load (Pelicano et al., 2004; Chandra and Singh,
2011; Israel and Schwartz, 2011; Perera and Bardeesy, 2011). It is
assumed that the majority of these ROS are side products of the
high metabolic activity of cancer cells, especially beta-oxidation
of fatty acids, and the activity of NADPH oxidases (Pelicano
et al., 2004; Cairns et al., 2011). However, this information has
a high degree of uncertainty, as a reliable genome-wide quantiﬁ-
cation of ROS contributions in cancer is lacking till the present
www.frontiersin.org January 2013 | Volume 2 | Article 212 | 5
“fonc-02-00212” — 2013/1/16 — 12:57 — page 6 — #6
Tosato et al. Two yeast models for cancer cells
day. Nonetheless, maintaining the redox balance appears to be a
major issue for mammalian tissue, indicated by the high concen-
tration of the anti-oxidant peptide glutathione, which exceeds the
cellular ATP level by an order of magnitude (Meister and Ander-
son, 1983). In tumors, PKM2 seems to fulﬁll a similar role in
anti-oxidant defense as discovered for yeast PYK genes. The low
activity of PKM2 in lung cancer cells leads to a higher activity of the
NADP reduction in the PPP, and to increased anti-oxidant defense.
Expressing of a oxidation-resistant PKM2 mutant in xenograft
tumors reduced the activity of the PPP, and markedly slowed
tumor growth (Anastasiou et al., 2011).
Overall, these observations indicate that the balancing of
the metabolic network (and so maintaining the redox state and
metabolite homeostasis) might be more difﬁcult to achieve for
rapidly proliferating cells than to guarantee a sufﬁcient supply
with ATP. Understanding this principle can be very valuable for
developing anti-cancer therapies. For instance, one could imagine
inducing a ROS boost into cancer cells for making them vulnera-
ble to chemotherapeutics (Perera and Bardeesy, 2011). The broad
experimental possibilities offered by yeast are invaluable help in
deciphering these complex questions.
Interestingly, recent results from several laboratories reveal that
a redirection of central carbon metabolism by PK does not only
change redox metabolism, but is also important for amino acid
metabolism (Bluemlein et al., 2012; Chaneton et al., 2012; Kung
et al., 2012; Ye et al., 2012). In yeast, a change in the activity
or expression level of PK causes a strong reconﬁguration of the
entire amino acid proﬁle, with seven amino acids (arginine, aspar-
tic acid, histidine, lysine, threonine, valine, and serine) being
present a lower concentration, and two amino acids (glutamine
and glutamate) being increased when PK activity is low (Bluem-
lein et al., 2012). Hence, PK seems to link the generation of energy
within central metabolism, and the metabolism around energy
consumption at the level protein biosynthesis.
In mammalian cells, the function of PKM2 in regulating ser-
ine biosynthesis has been studied in detail, and reveals a feedback
control system which controls the levels of free amino acids. It
has been found that serine is an allosteric activator of human
PKM2, and that overall PK activity is reduced when cancer cells
are deprived of this amino acid (Chaneton et al., 2012; Ye et al.,
2012). At the same time, the glycolytic block caused by reduced
PKM2 activity feeds back into serine biosynthesis, preventing ser-
ine deprivation during cancer formation (Chaneton et al., 2012).
Consistently, in human thyroid follicular adenoma, the expression
of the serine-biosynthetic enzyme serine hydroxymethyltrans-
ferase (SHMT1) is increased compared to healthy control tissue,
and correlates with the absolute PKM2 expression level (Bluem-
lein et al., 2012). In addition, small molecule activation of PKM2
induces serine auxotrophy in cancer cells, indicating that this
control mechanism could be exploited for therapeutic purposes
(Kung et al., 2012).
In sum, studies in yeast led to the discovery of redox state
control by the enzyme PK (Gruning et al., 2011). This mecha-
nism appears to be of importance for the progression of lung
cancer cells, but potentially other cancer types as well (Anas-
tasiou et al., 2011). PK further moonlights to the regulation of
protein biosynthesis, and amino acid metabolism in yeast and
human cells (Bluemlein et al., 2012; Chaneton et al., 2012). Serine
appears to be central for this regulatory mechanism, as it can act as
allosteric activator of PKM2 and hence report the concentration
of free amino acids to central carbon metabolism (Chaneton et al.,
2012; Ye et al., 2012). The PK enzyme is thus a central player in
coordinating cellular metabolism. Yeast turned out to be a very
effective model in studying the interplay of the involved metabolic
pathways.
SPONTANEOUS AND INDUCED CHROMOSOMAL
TRANSLOCATIONS
One of the best possibilities offered by the yeast system to model
gross genetic alterations known to induce well-characterized can-
cer forms in humans, is the BIT, bridge-induced chromosomal
translocation. Indeed, this technology induces the formation of
a translocated chromosome exploiting the yeast natural homol-
ogous recombination system (HRS) between the two ends of a
DNA bridge molecule harboring a positively selectable marker
(i.e., KANR). This type of chromosomal aberration has been since
long time connected to the insurgence of forms of tumors, like the
renowned Philadelphia chromosome, resulting from a transloca-
tion between chromosome 9 and 22 in humans, leading to CML.
Several other chromosomal translocations are known to promote
cancer and their molecular mechanisms of occurrence can be
studied efﬁciently in yeast, using the inducible BIT system. In
the following part, chromosomal translocations and BIT will be
deeply analyzed with respect to their cellular consequences leading
ultimately to cancer.
Chromosomal translocations are rare cellular phenomena in
which two chromosomes are interacting with each other either
by physical fusions or by copying one chromosome’s fragment on
another. Depending on the nature of these interactions, chro-
mosomal translocations can have reciprocal or non-reciprocal
conﬁguration. Translocations might pass unnoticed by the cell,
bringing no consequences; however, in the majority of cases, a
translocation’s onset has a tremendous impact, limited not only
to the single cell, but also to the organism as a whole. Chromoso-
mal translocations yield a variety of effects ranging from distorted
transcription patterns to cell death due to increased apoptosis.
In multicellular organisms, chromosomal translocations can be
related to a systemic death observed in human malignancies, in
particular hematological or mesenchymal cancers. As a result,
translocations can also be useful markers in the diagnosis of liquid
and solid tumors (Herve et al., 2011; Klemke et al., 2011). This fact
greatly increases interest in the investigation of all chromosomal
translocations aspects: origins, causes, outcomes, and clearly –
their association with genetic diseases. Despite the growing num-
ber of laboratories working on these subjects and the great efforts
made by investigators all over the world, the topic of chromo-
somal translocation is still not fully covered and the mechanistic
molecular factors that elicit these GCRs are still object of investi-
gation. Progresses are greatly impaired by the rare occurrence of
spontaneous translocations, in particular in mammalian cells, by
the broad panorama of secondary rearrangements and by a lack
of effective detection techniques.
Spontaneous chromosomal translocation can arise either from
spontaneous recombination between repeated elements dispersed
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through a genome or from the free DNA ends originated from
double-strand breaks (DSBs), stalled replication forks or dys-
functional telomeres (Jinks-Robertson and Petes, 1986; Loidl and
Nairz, 1997; Richardson et al., 1998). Although DSBs are an
extreme threat to the cell, they are crucial for its existence and
happen very frequently in a programmed manner as a part of
speciﬁc life cycle processes such as meiosis, mating type switch-
ing in fungi or V (D) J recombination during immunoglobulin
and T-cell receptors maturation (Bassing et al., 2002; Zhang et al.,
2011). DSBs can appear as a result of cellular processes like DNA
replication, through single-strand nicks, or elevated levels of ROS,
but they can be also induced by exogenous factors. Cell exposition
to DSBs-inducing agents (e.g., ionizing radiation, ROS, viruses,
some chemotherapeutic drugs, and more) greatly enhance the
probability of spontaneous translocations and teratogenicity, as
even a single DNA break in the cell can result in GCRs (Kolodner
et al., 2002). There exist two major, different DSB repair pathways:
homologous recombination (HR) and non-homologous end join-
ing (NHEJ), and both of them can give rise to translocations.
HR can occur by means of three sub-pathways: gene conver-
sion (GC), break induced replication (BIR), and single-strand
annealing (SSA). For a detailed review of these repair pathways
in mammalian and yeast cells the reader is referred to (Aylon
and Kupiec, 2004). Genome rearrangements, by deﬁnition, are
not beneﬁcial for the cell and will be actively prevented by various
mechanisms. For example, the choice of the correct repair pathway
(HR or NHEJ) at the right moment of the cell cycle is fundamen-
tal for the suppression of translocation (Branzei and Foiani, 2008).
In budding and ﬁssion yeast, HR is the dominating pathway for
DSB repair, and NHEJ seems to be restricted only to the G1 phase.
In fact, experiments indicate that NHEJ mutants of S. cerevisiae
are resistant to ionizing radiation, whereas HR mutations severely
compromise survival (Siede et al., 1996; Manolis et al., 2001). In
mammalian cells the situation is opposite. NHEJ is the dominat-
ing repair pathway employed during the entire cell cycle, whereas
HR is restricted to the S phase (van Gent and van der Burg, 2007;
Shrivastav et al., 2008). In effect, NHEJ pathway was originally
identiﬁed in mammals, and later its elements were discovered in
bacteria and yeasts (Moore and Haber, 1996; Doherty et al., 2001).
The prevalence of the HRS in budding yeast suggested its exploita-
tion in the production of “ad hoc” translocations in S. cerevisiae,
as described in the following paragraphs.
The broad spectrum of the effects of translocations and their
complex involvement into cancerogenic processes are the rea-
son why chromosomal translocations are so intensively studied.
Neoplastic transformation is associated to reciprocal or non-
reciprocal translocations that can lead to altered expression of
proto-oncogenes and loss of heterozygosity (LOH) of tumor
suppressor genes. Proto-oncogenes have their own homolog in
budding yeast (the most popular is SAS3, ortholog of MOZ) as
also do tumor suppressors (the yeast genes TEP1, FSH1, HNT2),
with the renowned exception of TP53.
The genetic mechanism through which chromosome translo-
cations elicit the onset of certain tumors is the fusion of the
coding sequence of two non-contiguous genes located at the
translocation site, on different chromosomes, with the conse-
quent expression of a novel hybrid protein able to disrupt the
correct control of cell proliferation. Usually, two major groups
of genes are involved into neoplastic transformation as an indi-
rect result of chromosome translocation: tyrosine kinases and
transcription factors. Oncogenic mechanisms of chimeric pro-
teins results from the cancer-promoting nature of such proteins
or by disruption of another gene regulation system. Novel gene
fusions caused by DSB repair are responsible for around 20% of
human cancer morbidity. Until now, 337 genes were identiﬁed
in 358 gene fusions (Mitelman et al., 2007). These numbers are
rapidly increasing due to development of rapid sequencing meth-
ods and constantly growing microarray databases. Identiﬁcation
of gene fusions gains remarkable importance as a diagnostic and
prognostic marker (Prensner and Chinnaiyan, 2009). The role of
chromosomal translocations in neoplasia is so signiﬁcant, that a
specialized database of chromosomal aberrations and gene fusions
in cancer has been created. This database can be accessed at:
http://cgap.nci.nih.gov/Chromosomes/Mitelman.
However, as mentioned before, one of the main problems
that researchers have to overcome is the extremely low frequency
of spontaneous translocations arising either in mammals or in
model systems. This negative aspect of the parallel between
human cancer cells and yeast could be overcome by the induc-
tion of chromosome translocation events in both cellular systems
with mutagenic agents. Unfortunately, any mutagenic process
utilized in mammalian cells would require the appearance of a
strong, detectable mutant phenotype to allow the selection of
those cells that have undergone a translocation event, and this
would occur very slowly and would be difﬁcult to select for.
On the contrary, with the model yeast cells, given the possi-
bility to manipulate an almost endless number of them and to
intervene more directly on their genome, this can be achieved
rather easily. In order to increase the events to reach statisti-
cally signiﬁcant numbers, various methods were developed for
induction of chromosomal translocations. Generally, these meth-
ods are based on two major principles: artiﬁcial induction of
DSBs within the desired regions sharing strong homology, or
recombination between special elements catalyzed by site-speciﬁc
recombinases. In both cases, a time-consuming molecular engi-
neering of the sites selected for the translocation, is necessary
prior the induction of the translocation event. Recently, a third
methodology of induction of chromosomal translocation has
been developed. This method, BIT, allows the generation of non-
reciprocal translocations in mitosis without pre-modiﬁcations of
the genome, exploiting the natural HRS of S. cerevisiae. The phe-
notypic changes of yeast cells after a BIT translocation event seem
tomimic closely the oncogenic transformationof mammalian cells
(Tosato et al., 2005). The most common methodologies to induce
GCRs and their implications are discussed extensively in the next
sections.
ADVANTAGES AND DRAWBACKS OF THE MAIN MOLECULAR
SYSTEMS TRIGGERING TRANSLOCATIONS
Several strategies to introduce DSBs by artiﬁcial means, ensuing
in chromosome translocations were developed in the last 15 years.
Transformation of yeast cells with a chromosomal fragmentation
vector (CFV) resulted in the gain of a chromosomal fragment (CF)
with or without the loss of the targeted chromosome, following
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DSB processing by break-copy duplication (Morrow et al., 1997).
The discovery of fragmental duplication in yeast led to demon-
strate, 1 year later, that a chromosomal DSB produced by the
HO endonuclease could be repaired by BIR, producing NHEJ-
mediated reciprocal translocation (Bosco and Haber, 1998). Later
on the HO system has been utilized for the production of a DSB on
two chromosomes, ensuing in reciprocal translocations by NHEJ
(Yu and Gabriel, 2004) after the repair of the broken chromo-
somes by SSA (Liddell et al., 2011). Other meganucleases, such as
I-SCEI, can be used to generate DSBs in higher organisms pro-
moting translocations with a frequency of 1–4% (Egli et al., 2004).
More recently, the cre site-speciﬁc recombination-based system
producing reciprocal translocations at pre-engineered loxP sites
has been developed to study speciation in yeasts (Delneri et al.,
2003) and successively improved to minimize the occurrence of
unwilled, secondary rearrangements (Carter and Delneri, 2010).
Finally, transposable elements are regularly utilized to produce
chromosomal manipulations with variable efﬁciencies. Among
all these systems, transposons-related methodology are mostly
exploited for the development of new variety of plants (Yu et al.,
2012), the cre-lox is used to generate animal models of human
cancers (Buchholz et al., 2000; Rabbitts et al., 2001; Forster et al.,
2005; Yu et al., 2010) although meganuclease-related methods are
also utilized to produce DSBs in malignant cell lines (Cheng et al.,
2010; Kitao et al., 2011). However, all these experimental systems
need preceding modiﬁcations of the genome in order to produce
translocations. Moreover, almost always they result in recipro-
cal translocations. It was therefore necessary to develop a simple
system that triggers translocations without any prerequisite for
strain engineering, without the assistance of any cloned exoge-
nous/endogenous enzyme and that allows also the simultaneous
recovery of events such as non-reciprocal translocations, telomeric
fusions anddeletions usually occurring duringneoplastic transfor-
mations. For these reasons the BIT methodology was developed.
BIT: BRIDGE-INDUCED TRANSLOCATION
THE BIT SYSTEM
The system consists in the production of selectable translocation-
derived recombinants (“translocants”) generated at desired chro-
mosomal locations in wild-type yeast strains transformed with
a linear DNA cassette carrying a selectable marker (i.e., KanR)
ﬂanked by two DNA sequences homologous to two different chro-
mosomes (Tosato et al., 2005; Figure 3). The bridge, which is
obtained exploiting the endogenous HR machinery of the yeast
cell, is obtained with a variable efﬁciency (typically from 2 to
15%) depending on the length of the homologies, the secondary
structures, and the base composition of the target regions, and the
strain’s genetic background. This last variability is probably due to
a different extension of the rDNA region of chromosome XII that
may act as recombination hotspot. It was demonstrated that the
resulting translocation is non-reciprocal, that it occurswith similar
efﬁciency between heterologous and homologous chromosomes
(Tosato et al., 2009) and that it is usually associated with aneu-
ploidy (Rossi et al., 2010). Effectively, we veriﬁed that several other
GCRs leading to LOH, such as intrachromosomal deletions, DNA
duplications, unspeciﬁc translocations due to micro-homology,
arose after transformation with the linear cassette.
FIGURE 3 | Schematic representation of a BIT chromosome
translocation event induced in the yeast S. cerevisiae, and its
molecular verification by PCR and Southern blot analysis. BIT
translocation designed between the ALD5 locus on chromosome V
and DUR3 on chromosome VIII and obtained by transformation with a
linear double-stranded DNA cassette having the two extremities
homologous to the two loci, ﬂanking the positively selectable marker
KANR . The translocation between the two top chromosomes, catalyzed by
the DNA cassette functioning as a bridge, produces the translocated
chromosome below the big gray arrow. Veriﬁcation of the correct
chromosome translocation by gel electrophoresis analysis of PCR
ampliﬁcation (bottom, left) of the two DNA junctions at the ALD5 and DUR3
loci (between primers indicated by the two small yellow arrows on the right
and the left, respectively), lanes ALD and DUR of the gel. Veriﬁcation of the
formation of the DNA bridge between the two chromosomes by PCR
ampliﬁcation of the region between the two external primers indicated by
the two small external yellow arrows, lane BRIDGE of the gel. Bottom,
right: Southern hybridization with a DNA probe corresponding to the KANR
gene, of a contour-clamped homogeneous electric ﬁeld (CHEF)
electrophoresis spread of chromosomes from a wild-type strain (lane wt), a
strain with chromosome VIII previously marked with KANR (lane VIII) and a
strain subjected to BIT translocation at the same loci (laneT).
GENERAL CELLULAR EFFECTS OF BIT TRANSLOCATION
As a consequence of a single translocation event produced via
BIT, the yeast cell exhibits an abnormal phenotype character-
ized by elongated buds, nucleated pseudo-hyphae, karyokinetic
defects and nuclear fragmentation (Nikitin et al., 2008; Rossi et al.,
2010). Moreover, the metabolism of the translocants was severely
impaired; they show, in particular, altered ﬁtness on different
carbon sources, different sporulation efﬁciencies and ability to
ﬂocculate. The integration of the same cassette at the two tar-
get loci can be processed in different ways generating strains
different in karyotype and consequently in phenotype and phys-
iology. These data suggest that the scrambling of gene regulation
throughout the genome triggered by the integration of a linear
DNA fragment through recombination is a great force for evolu-
tion. Indeed, among the broad panorama of mutants generated
by a translocation, few of them, or perhaps only one of them,
will be favored in survival and life span, adapting better to new
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environmental conditions or oxidative stress. That is exactly what
happens to the mammalian cells after neoplastic transformation,
when genomic defects are translated to phenotypic aberrations
and it represents the great plasticity and diversity of cancer
cells.
GENOME-WIDE EFFECTS ON REGULATION OF GENE EXPRESSION
It was demonstrated that the BIT system causes an increased
expression of the genes around the breakpoints up to ﬁve times (cis
effect), coinciding with an increased level of the RNA polymerase
II binding to their promoters, and with the pattern of histone
acetylation (Nikitin et al., 2008). Furthermore, many other genes
not involved in the speciﬁc translocation events are deregulated
(trans effect). Extensive transcriptome and ﬂuorescence-activated
cell sorting (FACS) analysis of the translocant pointed out that
the acentric chromosome fragments are duplicated or integrated
through micro-homology in the genome and that many cells are
blocked in G2/M phase. These results indicate that the translocant
cells have adapted to the checkpoint response after the initial DNA
damage induced by BIT. More recently, an implementation of the
BIT system was created in order to bridge together two homolo-
gous chromosomes in a diploid cell (Tosato et al., 2009). In this
case, the experiments demonstrated that BIThappenswith low fre-
quencies producing LOH and regions of hemizygosity by deletion.
The frequencyof targetedBITbetweenhomologous chromosomes
is lower or the same than between heterologs, supporting the idea
that a checkpoint system might actively prevent mitotic LOH in
eukaryotic diploid cells. The phenotypic and transcriptional aber-
rations of the translocant between homologous chromosomes are
negligible if compared to those of non-reciprocal translocants
between heterologs. Moreover, the quantitative analysis of the
expression of several genes around the breakpoints indicated the
over-expression of themulti-drug resistance geneVMR1. Remark-
ably, VMR1 is the budding yeast homolog to the human MRP4,
which is highly expressed in LOH-associated types of cancer such
as primary neuroblastoma (Norris et al., 2005).
ANEUPLOIDY
Recently, it was demonstrated that the HRS and the BIR pathway
are both responsible for the formation of the initial non-reciprocal
translocation and that the proximity of the targeted loci with
speciﬁc genomic elements, such as autonomously replicating
sequences (ARS) or repeated DNA regions,may inﬂuence not only
the efﬁciency of the event, but also the frequency of secondary
rearrangements and aneuploidies (Tosato and Rossi, personal
communication).
Aneuploidies are a landmark for cancer, but it is still not com-
pletely clear if they are an innocent by-product due to checkpoint
gene alterations or a driver of evolutionary processes leading to
neoplastic transformation. Further investigations of the molec-
ular players hidden behind the BIT system and responsible for
the primary and secondary rearrangements, will shed light to this
complex question.
FUTURE PERSPECTIVES AND CONCLUSIONS
In this short review we analyze some analogies between yeast and
cancer cells by the metabolic and genomic point of view. Typical
traits of a neoplastic transformation are loss of growth control,
the consequential continuous energetic demand and aneuploid
conditions due to genome instability. We found that in some
translocants, where clear phenotypic defects are visible, there are
also important metabolism impairments such as a reduced ﬁtness
to grow on glucose-deprived media. Effectively, after a wide pro-
teomic and transcriptomic analysis (Nikitin et al., 2008; Nikitin
and Bruschi, personal communication), we found that the trans
effect of BITdoes notmainly concern, as expected, recombination-
related genes, but on the contrary, metabolic genes. From a purely
logic point of view, to adapt to a different environmental con-
dition and to evolve (a malignant status is also an evolution)
the cells at ﬁrst must change their own metabolism. In this way,
the cellular ﬁtness will be improved and the new mutants will
be suddenly ready to overgrow the normal, low life span popu-
lation. To understand how to stop this amazing ability to adapt
and immortalize, we have to use simple single-cell models able
to retain an induced aneuploid status and chromosomal alter-
ations like telomere–telomere fusions, typical of many cancers.
The ideal organism is S. cerevisiae because it has a good amount
of chromosomes to play with, the best annotated genome, an
ability to survive and grow in haploid and diploid state, a sim-
ple switch between fermentation and respiration and a great
tolerance to ploidy variations. The phenotypic and metabolic
changes observed in Saccharomyces after a translocation resem-
ble some of the peculiarities observed in tumorigenesis. Studying
metabolism, experiments conducted in yeast are less biased com-
pared to mammalian cell culture, as culture conditions and genetic
background have strong inﬂuence on the status of the metabolic
network. Most routes of central metabolism are strongly con-
served between yeast and human, and it appears that the same is
true for basic control mechanisms. We have reviewed the reg-
ulatory function of yeast and human PK on metabolism, and
conclude that this enzyme presents a central and conserved coor-
dinator between energy production, ROS clearance, and amino
acid metabolism. Elaborating the principles of the metabolism
of rapidly proliferating cells (ROS quantitation, respiratory pro-
ﬁciencies) and extensively studying the altered genetic expression
in a collection of different BIT translocants will help ﬁnding the
effectors to revert, if not the altered karyotype, at least some abnor-
mal phenotype of aneuploid cancerogenic cells. In addition, this
straightforward technology could be extrapolated to higher organ-
isms to implement a molecular modeling of spontaneous genome
rearrangements leading to speciation in lower eukaryotes or LOH
in mammalian cells.
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